Therapie der Tic-Störungen
Abstract
Seit dem Erscheinen unserer letzten Übersichtsarbeit zur «Therapie der Tic-Störungen» in der Zeitschrift für Kinder- und Jugendpsychiatrie wurden große Fortschritte auf diesem Gebiet erzielt. So wurden einzelne Bausteine auf dem Weg zur optimalen Behandlung konkretisiert, z. B. Veröffentlichung einheitlicher Kriterien zur Behandlungsindikation oder Entwicklung und Evaluierung eines detaillierten verhaltenstherapeutischen Manuals zum Habit-Reversal-Training. Daneben sind neue Therapiemöglichkeiten, wie das Medikament Aripiprazol oder die Tiefenhirnstimulation, erfolgreich implementiert worden. Auch wurde das Augenmerk viel stärker auf begleitende Störungen, wie ADHS und Zwangsstörungen, gerichtet, da diese in der Regel eine besonders starke Beeinträchtigung für die weitere Entwicklung des Kindes oder Jugendlichen darstellen. Dennoch bestehen weiterhin große Wissenslücken über die Effektivität der einzelnen Behandlungsmethoden, möglicher Kombinationsbehandlungen sowie deren direkter Vergleich untereinander. Daneben erschwert das Fehlen jeglicher Parameter zur Vorhersage der individuell sehr unterschiedlichen Entwicklung der Tics über die nächsten Monate und Jahre eine evidenzbasierte Therapieempfehlung und damit das Erlernen der Feinheiten bei der Behandlung von Tic-Störungen. Zusammengefasst ist noch immer eine große klinische Erfahrung für die Therapieentscheidungen beim einzelnen Patienten von großem Vorteil angesichts der enormen Bandbreite an individueller Tic-Symptomatik und Komorbidität gepaart mit den unvorhersehbaren Schwankungen im zeitlichen Verlauf.
Tremendous progress has taken place in the last 8 years since the publication of our review on «Therapy of Tic Disorders» in the Zeitschrift für Kinder- und Jugendpsychiatrie. Several steps in treatment have been specified. For example, consensus-based indications for treatment have been published, and a detailed manual for a so-called habit-reversal training program has been developed and evaluated. In addition, new treatment options such as aripiprazole and deep-brain stimulation have been implemented. Increasing attention is being given to the disabling consequences of the commonly co-occurring psychiatric conditions known as ADHD or OCD. Nevertheless, there is still much to be learned about the treatment of tic disorders; standardized and sufficiently large drug trials in patients with tic disorders fulfilling evidence-based medicine standards are still scarce. The same is true for direct comparisons of different agents as well as of medication versus behavioral treatment. Finally, the question of how to predict the individual course of tics and how best to deal with the problems of waxing and waning of tics in this context still limits evidence base for treatment decisions. Large clinical experience is still a pre-requisite for making optimal decisions for the treatment of individual patients suffering from a tic disorder.
Literatur
(2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941–1949.
(2007). Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 558–565.
Arzneimittelinformationssystem. (2012). Verfügbar unter https://portal.dimdi.de/websearch/servlet/FlowController/SelectResult#__DEFANCHOR__
(1973). Habit-reversal: A method of eliminating nervous habits and tics. Behaviour Research and Therapy, 11, 619–628.
(1988). Habit reversal for the treatment of Tourette syndrome. Behaviour Research and Therapy, 26, 347–351.
(2003). Premonitory sensory phenomena and suppressibility of tics in Tourette syndrome: Developmental aspects in children and adolescents. Developmental Medicine and Child Neurology, 45, 700–703.
(2000). Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 28, 35–44.
(2000). Olanzapine in Tourette’s disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 140.
(1998). Relaxation therapy in Tourette syndrome: A pilot study. Pediatric Neurology, 18, 136–142.
(1998). Olanzapine in Tourette syndrome. The British Journal of Psychiatry, 172, 366.
(2005). Electrocardiographic changes in children and adolescents treated with ziprasidone: A prospective study. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 73–79.
(2011). Antibody binding to neuronal surface in Sydenham chorea, but not in PANDAS or Tourette syndrome. Neurology, 76, 1508–1513.
(2001). Risperidone versus pimozide in Tourette’s disorder: A comparative double-blind parallel-group study. Journal of Clinical Psychiatry, 62, 50–56.
(1988). Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette’s disorder. The American Journal of Psychiatry, 145, 621–624.
(2008). Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. Journal of Child and Adolescent Psychopharmacology, 18, 509–515.
(2001). An open-label study of the treatment efficacy of olanzapine for Tourette’s disorder. Journal of Clinical Psychiatry, 62, 290–294.
(
im Druck ). Fine motor skills and interhemispheric transfer in treatment-naïve boys with Tourette Syndrome. Developmental Medicine and Child Neurology.(1997). Case study: Adverse response to clonidine. J American Academy of Child and Adolescent Psychiatry, 36, 539–544.
(2012). From ipse dixit to evidence-based guidelines: On the optimal management of Tourette syndrome. European Journal of Paediatric Neurology.
(2011). Tolerability profile of aripiprazole in patients with Tourette syndrome. Journal of Psychopharmacology.
(2001). A school-based intervention designed to reduce the frequency of tics in children with Tourette’s syndrome. School Psychology Review, 30, 11–22.
(2007). Clinical effectiveness of quetiapine in children and adolescents with Tourette’s syndrome: A retrospective case-note survey. Clinical Drug Investigation, 27, 123–130.
(2011). Tolerability of quetiapine in children and adolescents with Tourette’s syndrome. The International Journal of Clinical Pharmacology and Therapeutics, 49, 177–178.
(2008). Examining cortisol rhythmicity and responsivity to stress in children with Tourette syndrome. Psychoneuroendocrinology, 33, 810–820.
(1989). A four-step hypnotherapy model for Gilles de la Tourette’s syndrome. The American Journal of Clinical Hypnosis, 31, 252–256.
(2006). Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls. Neurology, 66, 1612; author reply 1612.
(2007). Quetiapine in patients with Tourette’s disorder: An open-label, flexible-dose study. Journal of Clinical Psychiatry, 68, 1148–1150.
(2002). Risperidone in the treatment of tourette syndrome: A double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 22, 31–39.
(2010). Leitfaden Tic-Störungen. Göttingen: Hogrefe.
(1993). Sulpiride induced tardive dyskinesia in a person with Gilles de la Tourette syndrome. Journal of Psychopharmacology, 7, 290–292.
(1983). Neurobiological findings in children with tics and Gilles de la Tourette syndrome. In , Special aspects of psychopharmacology (pp. 191–202). Paris: Expansion Scientifique Francaise.
(1988a). Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. European Archives of Psychiatry Neurological Sciences, 237, 223–229.
(1988b). Tic-Krankheit. TW Pädiatrie, 1, 51–57.
(1993). Exacerbation and provocation of tics by imipramine and sulpiride. European Journal of Child and Adolescent Psychiatry, 2, 169–176.
(1994). Emergence of symptoms of Tourette’s syndrome during fluvoxamine treatment of obsessive-compulsive disorder. The British Journal of Psychiatry, 164, 839–841.
(2007). Tic disorders and ADHD: Answers from a world-wide clinical dataset on Tourette syndrome. European Journal of Child and Adolescent Psychiatry, 16(Suppl. 1), 15–23.
(2000). An international perspective on Tourette syndrome: Selected findings from 3,500 individuals in 22 countries. Developmental Medicine and Child Neurology, 42, 436–447.
(2010). A case of PANDAS treated with tetrabenazine and tonsillectomy. Journal of Child Neurology, 25, 614–615.
(1999). A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections. Biological Psychiatry, 45, 1564–1571.
(1993). Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome. Human Psychopharmacology: Clinical and Experimental, 8, 327–334.
(1985). Tardive dyskinesia in Tourette syndrome. Pediatric Neurology, 1, 192–194.
(2009). Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. European Neuropsychopharmacology, 19, 520–532.
(2011). Attentional performance in children and adolescents with tic disorder and co-occurring attention-deficit/hyperactivity disorder: New insights from a 2 × 2 factorial design study. Journal of Abnormal Child Psychology, 39, 819–828.
(2010). Oral Delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report. Journal of Clinicial Psychopharmacology, 30, 190–192.
(2009). Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. Journal of the Formosan Medical Association, 108, 788–793.
(2000). Olanzapine in Tourette’s disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 139.
(2001). Clonidine treatment increases tics in patients with Tourette syndrome: Case report. Journal of Child Neurology, 16, 380–381.
(2007). Schlafverhalten bei Kindern mit Tic-Störungen – Eine polysomnographische Studie. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 35, 119–126.
(1988). Treatment of extrapyramidal hyperkineses in childhood with tiapride. Psychiatrie, Neurologie und Medizinische Psychologie (Leipz), 40, 516–522.
(1999). Case series: Clonidine has no systematic effects on PR or QTc intervals in children. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1193–1196.
(1987). Relaxation-imagery (self-hypnosis) in Tourette syndrome: Experience with four children. The American Journal of Clinical Hypnosis, 29, 227–237.
(1996). Severe motor tics causing cervical myelopathy in Tourette’s syndrome. Movement Disorders, 11, 563–566.
(1998). Open-label olanzapine treatment in five preadolescent children. Journal of Child and Adolescent Psychopharmacology, 8, 107–113.
(2003). Tics and Tourette’s syndrome in childhood. Seminars in Pediatric Neurology, 10, 35–40.
(2000). Botulinum toxin in the treatment of tics. Archives of Neurology, 57, 1190–1193.
(2002). Tourette’s syndrome. The Lancet, 360, 1577–1586.
(2011). Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: A prospective longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 50, 108–118 e3.
(1986). Rebound phenomena in Tourette’s syndrome after abrupt withdrawal of clonidine: Behavioral, cardiovascular, and neurochemical effects. Archives of General Psychiatry, 43, 1168–1176.
(2001). Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS). The International Journal of Neuropsychopharmacology, 4, 191–198.
(1998). Clonidine: Adverse responses. Journal of Paediatrics and Child Health, 34, 501–502.
(1996). Predictors of clonidine response in Tourette syndrome: Implications and inferences. Journal of Child Neurology, 11, 93–97.
(1985). Tourette syndrome, pimozide, and school phobia: The neuroleptic separation anxiety syndrome. The American Journal of Psychiatry, 142, 613–615.
(2002). Olanzapine in Tourette’s syndrome: A report of three cases. Actas Espanolas de Psiquiatria, 30, 129–132.
(2009). Aripiprazole in children and adolescents with Tourette’s disorder: An open-label safety and tolerability study. Journal of Child and Adolescent Psychopharmacology, 19, 623–633.
(2002). Depression and dysphoria in adult and adolescent patients with Tourette’s disorder treated with risperidone. Journal of Clinical Psychiatry, 63, 1040–1044.
(2012). Aripiprazole in children with Tourette’s Disorder and Co-morbid Attention-Deficit/Hyperactivity Disorder: A 12-week, open-label, preliminary study. Journal of Child and Adolescent Psychopharmacology, 22, 120–125.
(1978). Utilisation du tiapride [
Therapeutic use of tiapride in movement disorders ]. La semaine des hôpitaux, 54, 517–520.(2011). Neurofeedback training for tourette syndrome: An uncontrolled single case study. Applied Psychophysiology and Biofeedback, 36, 281–288.
(2003). How to treat OCD in patients with Tourette syndrome. Journal of Psychosomatic Research, 55, 49–57.
(1981). School avoidance and social phobia triggered by haloperidol in patients with Tourette’s disorder. The American Journal of Psychiatry, 138, 1572–1576.
(1985). Habit reversal with muscle tics: Replication and component analysis. Behavior Therapy, 16, 39–50.
(2009). Serum autoantibodies measured by immunofluorescence confirm a failure to differentiate PANDAS and Tourette syndrome from controls. Journal of the Neurological Sciences, 276, 45–48.
(2003). Quetiapine treatment of children and adolescents with Tourette’s disorder. Journal of Child and Adolescent Psychopharmacology, 13, 295–299.
(1994). Blunted growth hormone response to clonidine in Gilles de la Tourette syndrome. Psychoneuroendocrinology, 19, 335–341.
(2004). Mycoplasma pneumoniae infection and Tourette’s syndrome. Psychiatry Research, 129, 119–125.
(2007). Die Benzamide Tiaprid, Sulpirid und Amisulprid in der Therapie des Tourette-Syndroms – Eine Standortbestimmung. Nervenarzt, 78,
264, 266–268, 270–271 .(2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: Deep brain stimulation. European Child and Adolescent Psychiatry, 20, 209–217.
(2011). Does Tourette syndrome prevent tardive dyskinesia? Movement Disorders, 26, 2442–2443.
(2003). Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial. Journal of Clinical Psychiatry, 64, 459–465.
(2009). Influence of sympathetic autonomic arousal on tics: Implications for a therapeutic behavioral intervention for Tourette syndrome. Journal of Psychosomatic Research, 67, 599–605.
(1995). Muscle control in chronic tic disorders. Biofeedback and Self Regulation, 20, 111–122.
(1997). A comparison of a behavioural and a cognitive-behavioural approach to the management of chronic tic disorders. Clinical Psychology and Psychotherapy, 4, 75–144.
(2001). Evaluation of a cognitive-behavioural program for the management of chronic tic and habit disorders. Behaviour Research and Therapy, 39, 667–681.
(2000). Olanzapine in severe Gilles de la Tourette syndrome: A 52-week double-blind cross-over study vs. low-dose pimozide. Journal of Neurology, 247, 443–446.
(1977). Reflections on child tics. Apropos of a therapeutic trial. Revue de Neuropsychiatrie Infantile, 25, 645–651.
(1999). Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. The Lancet, 354, 1153–1158.
(1992). An evaluation of behavioural treatments for Tourette syndrome. Behaviour Research and Therapy, 30, 167–174.
(2010). Behavior therapy for children with Tourette disorder: A randomized controlled trial. Journal of the American Medical Association, 303, 1929–1937.
(
im Druck ). Atypical antipsychotics for Tourette’s Syndrome. The Cochrane Database of Systematic Reviews.(2011). Metabolic and neurological complications of second-generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Drug Safety, 34, 651–668.
(1986). Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette’s syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 49, 791–795.
(1987). Tardive dyskinesia following haloperidol treatment in Tourette’s syndrome. Archives of General Psychiatry, 44, 98–99.
(1989). Pain in Gilles de la Tourette syndrome and related tic disorders. The Canadian Journal of the Neurological Sciences, 16, 439–441.
(2006). Mood disorders and Gilles de la Tourette’s syndrome: An update on prevalence, etiology, comorbidity, clinical associations, and implications. Journal of Psychosomatic Research, 61, 349–358.
(2008). The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 2: Tentative explanations for differing prevalence figures in GTS, including the possible effects of psychopathology, aetiology, cultural differences, and differing phenotypes. Journal of Psychosomatic Research, 65, 473–486.
(1990). Management of Gilles de la Tourette syndrome using sulpiride. Clinical Neuropharmacology, 13, 229–235.
(2000). Gilles de la Tourette syndrome: Symptomatic treatment based on evidence. European Child and Adolescent Psychiatry, 9(Suppl. 1), I60–75.
(2008). Normal response inhibition in boys with Tourette syndrome. Behavioral and Brain Functions, 4, 29.
(2004). Therapie der Tic-Störungen. Zeitschrift für Kinder- und Jugendpsychiatrie, 32, 245–263.
(2006). Verhaltenstherapie der Tic-Störungen. In , Lehrbuch der Psychotherapie (S. 549–561). München: CIP-Medien.
(2008a). Tic-Störungen. In , Lehrbuch der klinischen Psychologie und Psychotherapie (S. 321–333). Stuttgart: Thieme.
(2008b). Tic-Störungen und Tourette-Syndrom. In , Therapie psychischer Störungen im Kindes- und Jugendalter. Ein integratives Lehrbuch für die Praxis (S. 230–242). Stuttgart-New York: Thieme.
. (2007). Developmental psychopathology of children and adolescents with Tourette syndrome – impact of ADHD. European Child and Adolescent Psychiatry, 16(Suppl. 1), 24–35.
(2005). Tic disorders and obsessive compulsive disorder: Where is the link? Journal of Neural Transmission Suppemental, 69, 69–99.
(2007a). Executive functions in children with chronic tic disorders with/without ADHD: New insights. European Child and Adolescent Psychiatry, 16(Suppl. 1), 36–44.
(2007b). Psychopathological profile in children with chronic tic disorder and co-existing ADHD: Additive effects. Journal of Abnormal Child Psychology, 35, 79–85.
(2007c). Tic-Störungen und ADHS. In , ADHS und komorbide Erkrankungen im Kindes- und Erwachsenenalter (S. 60–72). Stuttgart: Kohlhammer.
(2008). Tic oder Zwang – eine schwierige, aber notwendige Differentialdiagnose. MMW, 150, 33–36.
(2011). Tourette’s disorder and other tic disorders in DSM-5: A comment. European Child and Adolescent Psychiatry, 20, 71–74.
(2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment. European Child and Adolescent Psychiatry, 20, 173–196.
(2006). First-onset tics in patients with attention-deficit-hyperactivity disorder: Impact of stimulants. Developmental Medicine and Child Neurology, 48, 616–621.
(
im Druck ). Pharmacological treatment of tics. In , Tourette Syndrome. New York: Oxford University Press.(2011). European clinical guidelines for Tourette syndrome and other tic disorders. European Child and Adolescent Psychiatry, 20, 153–154.
(1984). Therapie der Tic-Störungen. Zeitschrift für Kinder- und Jugendpsychiatrie, 12, 284–301.
(1991). Wenn Kinder Tics entwickeln. Stuttgart: Fischer.
(2007). Tic-Störungen. In , Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter (S. 319–325). Köln: Deutscher Ärzteverlag.
(2008). Tic-Störungen. In , Entwicklungspsychiatrie (S. 694–718). Stuttgart: Schattauer.
(1982). The influence of tiapride on the ERPs of children with multiple tics. In , Event-related potentials in children: Basic concepts and clinical applications (S. 423–428). Amsterdam: Elsevier.
(
im Druck ). Selbstregulation von Tics – Optimierung durch Neurofeedback. In , Neurofeedback – ein Arbeitsbuch. Stuttgart: Kohlhammer.(
im Druck ). The phenomenology of attention-deficit/hyperactivity disorder (ADHD) in Tourette Syndrome (TS) – modification while co-existing? In , Tourette Syndrome. New York: Oxford University Press.(2003). Pharmacodynamics of ziprasidone in children and adolescents: Impact on dopamine transmission. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 902–907.
(2000). Ziprasidone treatment of children and adolescents with Tourette’s syndrome: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 292–299.
(1997). Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder. The American Journal of Psychiatry, 154, 1057–1062.
(2003). Pharmacological management of tics in patients with TS. Journal of Psychosomatic Research, 55, 41–48.
(1990). Tourette syndrome: A follow-up study. Journal of Clinical Psychopharmacology, 10, 197–199.
(2005). Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. Journal of Psychopharmacology, 19, 205–206.
(2003). A placebo-controlled trial of risperidone in Tourette syndrome. Neurology, 60, 1130–1135.
(1982). ERP and drugs – proposal for a multivariante approach in studying drug effects by utilizing single ERP features. In , Event-related potentials in children. Amsterdam: Elsevier.
(2011). Tic disorders: Administrative prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample. European Psychiatry, 26, 370–374.
(2011). The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: A single-blind, randomised study. Human Psychopharmacology.
(1989). Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Archives of General Psychiatry, 46, 722–730.
(1998). Treatment of tic disorders with haloperidol. In , Tourette syndrome and tic disorders (S. 267–280). New York: Wiley.
(1993). Persistent tardive dyskinesia and other neuroleptic-related dyskinesias in Tourette’s disorder. Journal of Child and Adolescent Psychopharmacology, 3, 137–144.
(1995). Environmental factors and related fluctuation of symptoms in children and adolescents with Tourette’s disorder. The Journal of Child Psychology and Psychiatry, 36, 305–312.
(2001). Transdermal nicotine and haloperidol in Tourette’s disorder: A double-blind placebo-controlled study. Journal of Clinical Psychiatry, 62, 707–714.
(1991). Tourette syndrome and other tic disorders. Diagnosis, pathophysiology, and treatment. Medicine (Baltimore), 70, 15–32.
(2000). Effective open-label treatment of tourette’s disorder with olanzapine. International Clinical Psychopharmacology, 15, 23–28.
(2011). Defining treatment response in pediatric tic disorders: A signal detection analysis of the yale global tic severity scale. Journal of Child and Adolescent Psychopharmacology, 21, 621–627.
(1986). A simple and a complex tic (Gilles de la Tourette’s syndrome): Their response to EEG sensorimotor rhythm biofeedback training. International Journal of Psychophysiology, 4, 91–97.
. (2002). Treatment of ADHD in children with tics: A randomized controlled trial. Neurology, 58, 527–536.
(2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part III: Behavioural and psychosocial interventions. European Child and Adolescent Psychiatry, 20, 197–207.
(2008). Habituation of premonitory sensations during exposure and response prevention treatment in Tourette’s syndrome. Behavior Modification, 32, 215–227.
(2007). Tic suppression in the treatment of Tourette’s syndrome with exposure therapy: The rebound phenomenon reconsidered. Movement Disorders, 22, 1601–1606.
(2004). Exposure with response prevention versus habit reversal in Tourettes’s syndrome: A controlled study. Behaviour Research and Therapy, 42, 501–511.
(2012). Relationship of obsessive-compulsive disorder to age-related comorbidity in children and adolescents with tourette syndrome. Journal of Developmental and Behavioral Pediatrics, 33, 124–133.
(1987). Worsening of Tourette’s disorder due to neuroleptic-induced akathisia. The American Journal of Psychiatry, 144, 504–505.
(
im Druck ). Meta-analysis: Alpha-2 agonists in the treatment of tic disorders – moderating Effects of ADHD.(2000). Antipsychotic agents and QT changes. Journal of Psychiatry and Neuroscience, 25, 154–160.
(2003). Habit reversal versus supportive psychotherapy for Tourette’s disorder: A randomized controlled trial. The American Journal of Psychiatry, 160, 1175–1177.
(2011). Die Wirksamkeit der Reaktionsumkehr-Behandlung bei Kindern und Jugendlichen mit chronischen Tic-Störungen. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 39, 387–397.
(1988). A new hypnobehavioral method for the treatment of children with Tourette’s disorder. The American Journal of Clinical Hypnosis, 31, 97–106.
(2012). Peer victimization in youth with tourette syndrome and other chronic tic disorders. Child Psychiatry and Human Development, 43, 124–136.
